Pembrolizumab fails as monotherapy in breast cancer trial

But research continues to see whether it can benefit triple-negative patients in combination with chemo

A phase III trial of pembrolizumab for second- or third-line treatment of metastatic triple-negative breast cancer has failed to demonstrate superior overall survival compared to chemotherapy, manufacturer Merck has announced.